<DOC>
	<DOCNO>NCT01148524</DOCNO>
	<brief_summary>This Phase 2b/3 , multi-center , extension study V72P10 ass antibody persistence 18 month vaccination course study V72P10 ( NCT00661713 ) . Subjects participate study V72P10 , meet enrollment criterion extension study , group naïve subject ( define subject never receive rMenB+OMV NZ experimental MenB vaccine ) similar age subject eligible participate extension study , perform one study visit single blood sample drawn MenB serological analysis .</brief_summary>
	<brief_title>Assessment Antibody Persistence Eighteen Months After Completion Vaccination Course Study V72P10</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Informed consent obtain subject enrollment study nature study explain . Inclusion criterion naive subject , newly enrol : 1 . Healthy adolescent , 1319 year age ( age window define first day subject turn 13 year age day subject turn 20 year age ) . 2 . For Minor subject : subject give write assent whose parent legal guardian give write informed consent time enrollment , nature study explain . For Adult subject : subject give write informed consent time enrollment , nature study explain . 3 . Were available visit schedule study . 4 . Were good health determine medical history , physical examination , clinical judgment investigator . Inclusion criterion subject participate V72P10 study ( followon subject ) : 1 . For Minor subject : ( ≤18 year age ) subject give write assent whose parent legal guardian give write informed consent time enrollment , nature study explain . For Adult subject : ( old 18 year age ) subject give write informed consent time enrollment , nature study explain . 2. Who participate V72P10 study receive last vaccination 18 month ( 30 + 90 day ) enrollment V72P10E1 . 3. Who complete vaccination course study V72P10 , accord protocol . 4. Who provide least blood sample one month last vaccination V72P10 ( blood sample visit 6 , month 7 ) , accord protocol . 5 . Were available study visit schedule study . 6 . Were good health determine medical history , physical examination , clinical judgment investigator . Exclusion criterion naïve subject newly enrol : 1 . For Minor subject : subject unwilling unable give write informed assent participate study , whose parent ( ) /legal guardian ( ) unwilling unable give write informed consent participate study For Adult subject : subject unwilling unable give write informed consent participate study . 2 . History meningococcal B vaccine administration . 3 . Previous ascertain suspected disease cause N. meningitidis . 4 . Household contact and/or intimate exposure individual laboratory confirm N. meningitidis . 5 . Antibiotic treatment within 6 day prior enrollment . 6 . Any serious chronic progressive disease accord judgment investigator ( e.g. , neoplasm , diabetes mellitus Type I , cardiac disease , hepatic disease , neurological disease seizure , either associate fever part underlie neurological disorder syndrome , autoimmune disease , HIV infection AIDS , blood dyscrasia diathesis , sign cardiac renal failure severe malnutrition ) . 7 . Known suspected impairment/alteration immune system , immunosuppressive therapy , use systemic corticosteroid chronic use inhale highpotency corticosteroid within 30 day prior enrollment ( use low moderate dos inhale steroid exclusion ) ; 8 . Receipt blood , blood product and/or plasma derivative parenteral immunoglobulin preparation within 90 day prior enrollment . 9 . Participation another clinical trial within 90 day prior enrollment plan study . 10 . Family member household member study staff . 11 . Any condition , opinion investigator , could interfere evaluation study objective . Exclusion criterion subject participate V72P10 study ( followon subject ) : Exclusion criterion naïve subject , exception criterion 2 .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Meningococcal disease</keyword>
	<keyword>Vaccines</keyword>
	<keyword>Adolescents</keyword>
</DOC>